Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $40.5 million.

  • Lineage Cell Therapeutics' Cash & Current Investments rose 23.77% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.5 million, marking a year-over-year increase of 18.74%. This contributed to the annual value of $47.8 million for FY2024, which is 34.69% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Cash & Current Investments stood at $40.5 million, which was down 4.26% from $42.3 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Cash & Current Investments ranged from a high of $97.1 million in Q4 2022 and a low of $32.7 million during Q3 2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $42.3 million (2025), whereas its average is $42.1 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Cash & Current Investments skyrocketed by 239.47% in 2021, and later crashed by 63.46% in 2023.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Cash & Current Investments stood at $58.4 million in 2021, then soared by 66.46% to $97.1 million in 2022, then plummeted by 63.46% to $35.5 million in 2023, then surged by 34.69% to $47.8 million in 2024, then grew by 23.77% to $40.5 million in 2025.
  • Its Cash & Current Investments stands at $40.5 million for Q3 2025, versus $42.3 million for Q2 2025 and $47.9 million for Q1 2025.